Wang D, Chen J, Zhang X, et al. - In this study with 40 patients with stage III non-small cell lung cancer, researchers quantified the dosimetric benefits of simultaneous integrated boost volumetric modulated arc therapy (SIB-VMAT). For every patient, experts generated SIB-VMAT and conventional VMAT (C-VMAT) plans by employing the automatic treatment planning system. They delivered a decreased dose to PTV in SIB-VAMT plans vs C-VMAT plans (50.4Gy vs 60Gy). Using the quality score, they assessed organs at risk protection for two type prescription plans. According to the findings, a substantial sparing of normal organs, including lung, heart, esophagus and cord could be attained, mainly via attenuation of high and inter-median dose exposure, as a result of using SIB-VMAT technique. SIB-VMAT might be more beneficial for patients with CTV/(GTV+GTVnd) ≥ 8.6.